In vivo supramolecular templating enhances the activity of multivalent ligands: A potential therapeutic against the Escherichia coli O157 AB5 toxins

被引:65
作者
Kitov, Pavel I. [1 ]
Mulvey, George L. [2 ]
Griener, Thomas P. [2 ]
Lipinski, Tomasz [1 ]
Solomon, Dmitry [1 ]
Paszkiewicz, Eugenia [1 ]
Jacobson, Jared M. [1 ]
Sadowska, Joanna M. [1 ]
Suzuki, Missao [3 ]
Yamamura, Ken-ichi [3 ]
Armstrong, Glen D. [2 ]
Bundle, David R. [1 ]
机构
[1] Univ Alberta, Dept Chem, Alberta Ingenu Ctr Carbohydrate Sci, Edmonton, AB T6G 2G2, Canada
[2] Univ Calgary, Dept Microbiol & Infect Dis, Alberta Ingenu Ctr Carbohydrate Sci, Calgary, AB T2N 4N1, Canada
[3] Kumamoto Univ, Sch Med, Inst Mol Embryol & Genet, Kumamoto 8620976, Japan
基金
加拿大自然科学与工程研究理事会;
关键词
heterobifunctional ligand; multivalency; Shiga toxin;
D O I
10.1073/pnas.0804919105
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
We demonstrate that interactions between multimeric receptors and multivalent ligands are dramatically enhanced by recruiting a complementary templating receptor such as an endogenous multimeric protein but only when individual ligands are attached to a polymer as preorganized, covalent, heterobifunctional pairs. This effect cannot be replicated by a multivalent ligand if the same recognition elements are independently arrayed on the scaffold. Application of this principle offers an approach to create high-avidity inhibitors for multimeric receptors. Judicious selection of the ligand that engages the templating protein allows appropriate effector function to be incorporated in the polymeric construct, thereby providing an opportunity for therapeutic applications. The power of this approach is exemplified by the design of exceptionally potent Escherichia coli Shiga toxin antagonists that protect transgenic mice that constitutively express a human pentraxin, serum amyloid P component.
引用
收藏
页码:16837 / 16842
页数:6
相关论文
共 34 条
  • [11] On the nature of the multivalency effect: A thermodynamic model
    Kitov, PI
    Bundle, DR
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2003, 125 (52) : 16271 - 16284
  • [12] Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands
    Kitov, PI
    Sadowska, JM
    Mulvey, G
    Armstrong, GD
    Ling, H
    Pannu, NS
    Read, RJ
    Bundle, DR
    [J]. NATURE, 2000, 403 (6770) : 669 - 672
  • [13] Promotion of opsonization by antibodies and phagocytosis of Gram-positive bacteria by a bifunctional polyacrylamide
    Krishnamurthy, VM
    Quinton, LJ
    Estroff, LA
    Metallo, SJ
    Isaacs, JM
    Mizgerd, JP
    Whitesides, GM
    [J]. BIOMATERIALS, 2006, 27 (19) : 3663 - 3674
  • [14] Protein heterodimerization through ligand-bridged multivalent pre-organization: Enhancing ligand binding toward both protein targets
    Liu, JY
    Zhang, ZS
    Tan, XJ
    Hol, WGJ
    Verlinde, CLMJ
    Fan, EK
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2005, 127 (07) : 2044 - 2045
  • [15] Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential
    Lu, YJ
    Sega, E
    Leamon, CP
    Low, PS
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2004, 56 (08) : 1161 - 1176
  • [16] Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors
    Lu, YJ
    Low, PS
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2002, 51 (03) : 153 - 162
  • [17] The cluster glycoside effect
    Lundquist, JJ
    Toone, EJ
    [J]. CHEMICAL REVIEWS, 2002, 102 (02) : 555 - 578
  • [18] Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755
  • [19] Serum amyloid P component binding to Shiga toxin 2 requires both A subunit and B pentamer
    Marcato, P
    Vander Helm, K
    Mulvey, GL
    Armstrong, GD
    [J]. INFECTION AND IMMUNITY, 2003, 71 (10) : 6075 - 6078
  • [20] Production and characterization of protective human antibodies against shiga toxin 1
    Mukherjee, J
    Chios, K
    Fishwild, D
    Hudson, D
    O'Donnell, S
    Rich, SM
    Donohue-Rolfe, A
    Tzipori, S
    [J]. INFECTION AND IMMUNITY, 2002, 70 (10) : 5896 - 5899